Potential additive effects of garcinia cambogia on atorvastatin treated hyperlipidemic patients: randomized crossover clinical study


  • Hayder M. Alkuraishy Department of Pharmacology, Toxicology and Medicine, College of Medicine, Al-Mustansiriya University, Iraq, Baghdad
  • Ali I. Algareeb Department of Pharmacology, Toxicology and Medicine, College of Medicine, Al-Mustansiriya University, Iraq, Baghdad
  • Ali K. Albuhadilly Department of Pharmacology and Medicine, College of Medicine, Al-Mustansiriya University, Iraq, Baghdad
  • Basim M. ALmgoter Department of Clinical Pharmacology, College of Medicine, Al-Mustansiriya University, Iraq, Baghdad


Hyperlipidemia, Atorvastatin, Garcinia cambogia


Background: Dyslipidemia is a major risk factor linking in the direction of the progression of ischemic heart diseases, which is measured to be the chief principal reason of international morbidity and mortality. Numerous lessons seeming for substitute treatments include attempted herbal medicine for reducing the expansion of ischemic heart and vascular diseases. Along with herbs with hypolipidemic actions were garlic, garcinia cambogia, gum guggul and others plants. Garcinia cambogia is an herbal agent found in different fruit plants inhibit lipid synthesis via its active materials hydroxycitric acid that inhibit cytoplasmic adenosine triphosphate-dependent citrate lyase, which responsible for hepatic lipogenesis in dose dependent manner. Thus, the objective of this experimental research was for elucidation the potential combined effects of atorvastatin and garcinia cambogia resting on lipid profile in hyperlipidemic patients.

Methods: A total of 25 hyperlipidemic patients enrolled in this clinical trial under scientific approval committee and spoken consent taken from all patients. Five patients were withdrawn from this study due to incompliance so, only 20 patients (12 males + 8 females) continue this clinical trial. All patients not took any medications through 2 weeks and all non-diabetic or hypertensive with age ranged 45-65 years. The patients divided into two groups: Group A: 10 patients (4 females + 6 males) take atorvastatin 40/day. Group B: 10 patients (6 males + 4 females) take atorvastatin 40/day + garcinia cambogia 500/day. The duration of treatment was 8 weeks, and baseline lipid profile measurements were done and regarded as control.

Results: The atorvastatin effects during 8 weeks treatment at dose of 40 mg/day produced significant effects on all lipid profile p < 0.05, mainly on serum cholesterol and low-density lipoprotein (LDL) levels and less significant effects on atherogenic index (AI), triglyceride and very LDL (VLDL). While garcinia cambogia produced significant reductions in serum lipid and improve other lipid parameters, garcinia cambogia 500 mg/day significantly improve serum cholesterol, VLDL, and LDL p < 0.05 but produced insignificant effect on high-density lipoprotein and AI p >0.05. The combined effects of garcinia cambogia 500 mg/day and atorvastatin 40 mg/day showed significant effects on all lipid profiles and AI p < 0.05.

Conclusion: This study scrutinizes the value of garcinia cambogia in treatment of hyperlipidemia alone or in combination with atorvastatin. It produced significant additive effect with atorvastatin and hence atorvastatine doses can be reduced and substituted with garcinia cambogia for reduction serious atorvastatin associated adverse effects.


Expert Dyslipidemia Panel of the International Atherosclerosis Society Panel members. An International Atherosclerosis Society Position Paper: global recommendations for the management of dyslipidemia – Full report. J Clin Lipidol. 2014;8(1):29-60.

Haiyun W, Jianwei B, Jiao G. Chinese herbal medicine for treatment of dislipidemia. J Geriatr Cardiol. 2009;6(2):45-9.

El-Missiry A, Othman I. Role of herbal extracts in the prevention of oxidative stress and modulation of atherogenic risk factors in experimentally-induced DM. Diabetes Metab. 2012;38(5):107-8.

Musharraf SG, Iqbal N, Gulzar U, Ali A, Choudhary MI, Atta-Ur-Rahman. Effective separation and analysis of E- and Z-guggulsterones in Commiphora mukul resin, guggulipid and their pharmaceutical product by high performance thin-layer chromatography-densitometric method. J Pharm Biomed Anal. 2011;56(2):240-5.

Chen J, Zhao H, Yang Y, Liu B, Ni J, Wang W. Lipid-lowering and antioxidant activities of Jiang-Zhi-Ning in Traditional Chinese Medicine. J Ethnopharmacol. 2011;134(3):919-30.

Kim YJ, Choi MS, Park YB, Kim SR, Lee MK, Jung UJ. Garcinia Cambogia attenuates diet-induced adiposity but exacerbates hepatic collagen accumulation and inflammation. World J Gastroenterol. 2013;19(29):4689-701.

Toman O, Novotny T, Sisakova M, Hnatkova K, Andrsova I, Parenica J, et al. Effect of atorvastatin on dynamic parameters of myocardial repolarization in healthy subjects. J Electrocardiol. 2012;45(6):752-7.

Han L, Li M, Liu Y, Han C, Ye P. Atorvastatin may delay cardiac aging by upregulating peroxisome proliferator-activated receptors in rats. Pharmacology. 2012;89(1-2):74-82.

Momi S, Monopoli A, Alberti PF, Falcinelli E, Corazzi T, Conti V, et al. Nitric oxide enhances the anti-inflammatory and anti-atherogenic activity of atorvastatin in a mouse model of accelerated atherosclerosis. Cardiovasc Res. 2012;94(3):428-38.

Han KH, Rha SW, Kang HJ, Bae JW, Choi BJ, Choi SY, et al. Evaluation of short-term safety and efficacy of HMG-CoA reductase inhibitors in hypercholesterolemic patients with elevated serum alanine transaminase concentrations: PITCH study (PITavastatin versus atorvastatin to evaluate the effect on patients with hypercholesterolemia and mild to moderate hepatic damage). J Clin Lipidol. 2012;6(4):340-51.

Yang SS, Li R, Qu X, Fang W, Quan Z. Atorvastatin decreases Toll-like receptor 4 expression and downstream signaling in human monocytic leukemia cells. Cell Immunol. 2012;279(1):96-102.

Uydu HA, Yildirmis S, Orem C, Calapoglu M, Alver A, Kural B, et al. The effects of atorvastatin therapy on rheological characteristics of erythrocyte membrane, serum lipid profile and oxidative status in patients with dyslipidemia. J Membr Biol. 2012;245(11):697-705.

Supakul L, Pintana H, Apaijai N, Chattipakorn S, Shinlapawittayatorn K, Chattipakorn N. Protective effects of garlic extract on cardiac function, heart rate variability, and cardiac mitochondria in obese insulin-resistant rats. Eur J Nutr. 2014;53(3):919-28.

Arunima S, Rajamohan T. Influence of virgin coconut oil-enriched diet on the transcriptional regulation of fatty acid synthesis and oxidation in rats - a comparative study. Br J Nutr. 2014;111(10):1782-90.

Adel E, Amira R. Cytogenetic and biochemical studies on the effect of DDB in Albino mice and their embryos. Egypt J Hosp Med. 2007;28(4):439-47.

Bhardwaj G, Bhattacharjee J, Bhatnagar M, Tyagi S. Atherogenic index of plasma, castelli risk index and atherogenic coefficient - new parameters in assessing cardiovascular risk. Int J Pharm Biol Sci. 2013;3(3):359-64.

Walker PL, Crook MA. Lipaemia: causes, consequences and solutions. Clin Chim Acta. 2013;418:30-2.

Jarauta E, Mateo-Gallego R, Gilabert R, Plana N, Junyent M, de Groot E, et al. Carotid atherosclerosis and lipoprotein particle subclasses in familial hypercholesterolaemia and familial combined hyperlipidaemia. Nutr Metab Cardiovasc Dis. 2012;22(7):591-7.

National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. Circulation. 2002;106:3143-421.

El-Moselhy MA, El-Sheikh AA. Protective mechanisms of atorvastatin against doxorubicin-induced hepato-renal toxicity. Biomed Pharmacother. 2014;68(1):101-10.

Shin HS, Han JM, Kim HG, Choi MK, Son CG, Yoo HR, et al. Anti-atherosclerosis and hyperlipidemia effects of herbal mixture, artemisia iwayomogi kitamura and Curcuma longa Linne, in apolipoprotein E-deficient mice. J Ethnopharmacol. 2014;153(1):142-50.

Jenkins DJ, Kendall CW, Garsetti M, Rosenberg-Zand RS, Jackson CJ, Agarwal S, et al. Effect of soy protein foods on low-density lipoprotein oxidation and ex vivo sex hormone receptor activity – A controlled crossover trial. Metabolism. 2000;49(4):537-43.

Offermanns S. Free fatty acid (FFA) and hydroxy carboxylic acid (HCA) receptors. Annu Rev Pharmacol Toxicol. 2014;54:407-34.

Asghar M, Monjok E, Kouamou G, Ohia SE, Bagchi D, Lokhandwala MF. Super CitriMax (HCA-SX) attenuates increases in oxidative stress, inflammation, insulin resistance, and body weight in developing obese Zucker rats. Mol Cell Biochem. 2007;304(1-2):93-9.

Ishihara K, Oyaizu S, Onuki K, Lim K, Fushiki T. Chronic (-)-hydroxycitrate administration spares carbohydrate utilization and promotes lipid oxidation during exercise in mice. J Nutr. 2000;130(12):2990-5.

Preuss HG, Bagchi D, Bagchi M, Rao CV, Dey DK, Satyanarayana S. Effects of a natural extract of (-)-hydroxycitric acid (HCA-SX) and a combination of HCA-SX plus niacin-bound chromium and Gymnema sylvestre extract on weight loss. Diabetes Obes Metab. 2004;6(3):171-80.

Nadler ST, Stoehr JP, Schueler KL, Tanimoto G, Yandell BS, Attie AD. The expression of adipogenic genes is decreased in obesity and diabetes mellitus. Proc Natl Acad Sci U S A. 2000;97:11371-6.

Kolodziejczyk J, Masullo M, Olas B, Piacente S, Wachowicz B. Effects of garcinol and guttiferone K isolated from Garcinia cambogia on oxidative/nitrative modifications in blood platelets and plasma. Platelets. 2009;20(7):487-92.

Jenkins DJ, Kendall CW, Vidgen E, Mehling CC, Parker T, Seyler H, et al. The effect on serum lipids and oxidized low-density lipoprotein of supplementing self-selected low-fat diets with soluble-fiber, soy, and vegetable protein foods. Metabolism. 2000;49(1):67-72.

Beltowski J. Statins and modulation of oxidative stress. Toxicol Mech Methods. 2005;15(2):61-92.

Danesh FR, Kanwar YS. Modulatory effects of HMG-CoA reductase inhibitors in diabetic microangiopathy. FASEB J. 2004;18(7):805-15.

Liao JK, Laufs U. Pleiotropic effects of statins. Annu Rev Pharmacol Toxicol. 2005;45:89-118.

Rang P, Dale M. Text Book of Pharmacology. 5th Edition. Philadelphia: Churchill Living Stone; 2003: 306-13.

Naeem A, Drackley JK, Stamey J, Loor JJ. Role of metabolic and cellular proliferation genes in ruminal development in response to enhanced plane of nutrition in neonatal Holstein calves. J Dairy Sci. 2012;95(4):1807-20.

Oluyemi KA, Omotuyi IO, Jimoh OR, Adesanya OA, Saalu CL, Josiah SJ. Erythropoietic and anti-obesity effects of Garcinia cambogia (bitter kola) in Wistar rats. Biotechnol Appl Biochem. 2007;46:69-72.

Dobiásová M, Frohlich J, Sedová M, Cheung MC, Brown BG. Cholesterol esterification and atherogenic index of plasma correlate with lipoprotein size and findings on coronary angiography. J Lipid Res. 2011;52(3):566-71.

Hermans MP, Sacks FM, Ahn SA, Rousseau MF. Non-HDL-cholesterol as valid surrogate to apolipoprotein B100 measurement in diabetes: discriminant Ratio and unbiased equivalence. Cardiovasc Diabetol. 2011;10:20.






Original Research Articles